Efficacy, immunogenicity and safety study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese adults aged ≥50 years

Trial Identifier: 212884
Sponsor: GlaxoSmithKline
Start Date: May 2021
Primary Completion Date: April 2023
Study Completion Date: April 2023
Condition: Other - Conditions

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Lianyungang, China, 222100
China Shanghai, China, 200051
China Shanghai, China, 201620
China Shanghai, China, 200090
China Shanghai, China, 200001
China, Jiangsu Huaian, Jiangsu, China, 223005